Penn study finds mechanism that regulates lung function in disease Birt-Hogg-Dube syndrome

(Press-News.org) (PHILADELPHIA) – Researchers at Penn Medicine have discovered that the tumor suppressor gene folliculin (FLCN) is essential to normal lung function in patients with the rare disease Birt-Hogg-Dube (BHD) syndrome, a genetic disorder that affects the lungs, skin and kidneys. Folliculin's absence or mutated state has a cascading effect that leads to deteriorated lung integrity and an impairment of lung function, as reported in their findings in the current issue of Cell Reports.

"We discovered that without normal FLCN the alveolar epithelial cells (AEC) in these patients' lungs began to die, leading to holes in the lungs that grow as increasing numbers of cells disappear. These holes can fill with air and burst, causing the lungs to collapse," says Vera Krymskaya, PhD, MBA, associate professor of Medicine at the Perelman School of Medicine at the University of Pennsylvania, and researcher in the Airway Biology Initiative of the department of Pulmonary, Allergy and Critical Care.

Between 80 and 100 percent of patients with BHD will develop multiple holes or cysts in the lung.

Healthy human alveoli, the terminal ends of the respiratory tree, are lined with type I and type II alveolar epithelial cells (AECs), a renewable population of progenitors in these distal airspaces. AECs are known to maintain pulmonary alveolar homeostasis by regulating gas exchange and fluid transport in the lungs.

Previous studies have shown that there might be some crosstalk between FLCN and the master energy sensor AMP-activated protein kinase (AMPK). AMPK maintains epithelial cell to cell interactions and is essential for epithelial cell survival. It is regulated through LKB1, a tumor suppressor gene associated with 30 percent of lung cancers. E-cadherin, the "zipper" molecule that connects epithelial cells, directs LKB1 to cell junctions and its loss impairs LKB1-mediated AMPK activation. This implies that a loss of or mutation in FLCN can trigger a reaction that can impair AMPK activation, epithelial cell to cell interaction and structure, and as a result, promotes cell death.

Penn researchers set out to examine this hypothesis to determine how and why this occurs.

Krymskaya and her team tested both deleted FLCN in mouse lung type II alveolar epithelial cells and mutated FLCN that lacked normal function in both humans with BHD and mouse epithelial cell systems, and compared them with normal human and mouse control cells.

The control cells showed normal epithelial structure, while the mutated FLCN cells showed irregular and disrupted lung cell structure. In addition, the BHD lungs showed very little FLCN in the type II alveolar epithelial cells.

Next, to evaluate the role of FLCN in the lung, the team isolated the alveolar epithelial cells from the mice with FLCN and deleted the gene in vitro to show the decreased cell to cell interactions and increased cellular permeability. They also examined activity of AMPK in these cells and saw that cells were dying without FLCN, so there was not proper activation of AMPK.

FLCN-deficient mice were also given a doxycycline supplement to conditionally delete FLCN specifically in alveolar epithelial type II cells both during embryonic development and as adults. Newborns experienced developmental changes induced by FLCN deletion in the lung epithelium. Over time, these morphed into changes that resembled emphysema, such as alveolar enlargement and a decline in lung elasticity and pulmonary function.

Further, the Penn researchers are the first to demonstrate the mechanism by which FLCN begins the domino effect necessary for normal lung function. Examination of cells with FLCN mutations shows that FLCN downregulates E-cadherin and LKB1 which controls AMPK activity. FLCN also maintains alveolar surface tension preventing the lungs from collapse, as seen in BHD disease. Without this, the lung changes associated with BHD and other common and rare lung diseases begin to appear: the abnormal enlargement of airspaces among them.

The team then showed that in fact, AMPK is necessary for epithelial cells survival. Importantly, using mouse BHD model, investigators show beneficial effect of pharmacological activator of AMPK AICAR, an AMPK stimulator, on lung function.

"AMPK is the metabolic regulator of the alveolar epithelial cells," says Krymskaya. "We may be able to reverse cell death if we can find a way to activate AMPK therapeutically in patients with less than optimal or mutated FLCN."

INFORMATION:

This project was supported by the NIH's Intramural Research Program, Frederick National Laboratory for Cancer Research and the Center for Cancer Research as well as the National Heart, Lung and Blood Institute R01 HL110551, and the Myrovyltis Trust.

Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.

The Perelman School of Medicine has been ranked among the top five medical schools in the United States for the past 17 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $392 million awarded in the 2013 fiscal year.

The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top "Honor Roll" hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; Chester County Hospital; Penn Wissahickon Hospice; and Pennsylvania Hospital -- the nation's first hospital, founded in 1751. Additional affiliated inpatient care facilities and services throughout the Philadelphia region include Chestnut Hill Hospital and Good Shepherd Penn Partners, a partnership between Good Shepherd Rehabilitation Network and Penn Medicine.

Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2013, Penn Medicine provided $814 million to benefit our community.